Academy of Finland
Funding decision
 
Name Tuomela, Johanna
Organisation University of Turku
Project title Bisfosfonaattien aiheuttaman tulehdusreaktion kliininen merkitys
Decision No. 308375
Decision date 28.04.2017
Funding,period 01.09.2017 - 31.08.2021
Funding 448 849
WebFOCUS Report
Project description
Bisphosphonates (BP) have been in clinical use as osteoporosis drugs and in oncology to prevent bone fractures for nearly three decades. They are also shown to have direct anti-cancer effects also in soft tissues. Although BPs are used in oncology, we lack biomarkers for finding patients that benefit from the treatment. According to our hypothesis, BPs have, in addition to classical mechanism, another inflammation-based mechanism that actually causes beneficial effects on cancer. We have recently found a subgroup of triple-negative breast cancer that is more sensitive to BP-treatment than other subgroups. This subgroup expresses very little the innate immunity receptor TLR9. Until now, there are no targeted therapies to that subgroup. In this project, we study the use of TLR9 as a biomarker for BP-sensitive tumors. Our results of BP mechanisms of action can also be used in new BP drug development.